Skip To Main Content
Stephane Kroudia on Muck Rack

Stephane Kroudia

As seen in: BMC Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Stephane

Contact Stephane, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Impact of lenalidomide consolidation on health-related quality of life in chronic lymphocytic leukemia: ancillary study of the phase III CLL6-RESIDUUM trial | BMC Cancer | Full Text

|
By Dijon Cedex, Institut Paoli Calmettes, Stephane Kroudia, Sandrine Tienhan
| BMC Cancer Verified
The CLL6 RESIDUUM trial was a phase III randomized clinical trial of the ALLG and the FILO. Eligibility criteria were CLL patients with detectable residual disease after front-line ICT according to iwCLL guidelines [7]. Patients should have received at least 4 and at most 6 cycles of FCR. Residual disease was considered when detected at a level of at least 10–4 in multiparameter flow cytometry of peripheral blood or bone marrow, or when visualized through radiological evaluation.
Open in Who Shared Issue with article?
See all 1 articles